References
Chapter 1
1. Cannavino CR, et al. Pediatr Infect Dis J. 2016;35(7):752–759 PMID: 27093162
2. Blumer JL, et al. Pediatr Infect Dis J. 2016;35(7):760–766 PMID: 27078119
3. Korczowski B, et al. Pediatr Infect Dis J. 2016;35(8):e239–e247 PMID: 27164462
4. Bradley JS, et al. Pediatrics. 2011;128(4):e1034–e1045 PMID: 21949152
5. Bradley JS, et al. Pediatrics. 2014;134(1):e146–e153 PMID: 24918220
Chapter 2
1. Cornely OA, et al. Clin Infect Dis. 2007;44(10):1289–1297 PMID: 17443465
2. Ascher SB, et al. Pediatr Infect Dis J. 2012;31(5):439–443 PMID: 22189522
3. Piper L, et al. Pediatr Infect Dis J. 2011;30(5):375–378 PMID: 21085048
4. Friberg LE, et al. Antimicrob Agents Chemother. 2012;56(6):3032–3042 PMID: 22430956
5. Smith PB, et al. Pediatr Infect Dis J. 2009;28(5):412–415 PMID: 19319022
6. Hope WW, et al. Antimicrob Agents Chemother. 2010;54(6):2633–2637 PMID: 20308367
7. Benjamin DK Jr, et al. Clin Pharmacol Ther. 2010;87(1):93–99 PMID: 19890251
8. Cohen-Wolkowiez M, et al. Clin Pharmacol Ther. 2011;89(5):702–707 PMID: 21412233
Chapter 4
1. Liu C, et al. Clin Infect Dis. 2011;52(3):e18–e55 PMID: 21208910
2. Le J, et al. Pediatr Infect Dis J. 2013;32(4):e155–e163 PMID: 23340565
3. Depardieu F, et al. Clin Microbiol Rev. 2007;20(1):79–114 PMID: 17223624
4. Miller LG, et al. N Engl J Med. 2015;372(12):1093–1103 PMID: 25785967
5. Korczowski B, et al. Pediatr Infect Dis J. 2016;35(8):e239–e247 PMID: 27164462
6. Cannavino CR, et al. Pediatr Infect Dis J. 2016;35(7):752–759 PMID: 27093162
7. Blumer JL, et al. Pediatr Infect Dis J. 2016;35(7):760–766 PMID: 27078119
8. Huang JT, et al. Pediatrics. 2009;123(5):e808–e814 PMID: 19403473
9. Finnell SM, et al. Clin Pediatr (Phila). 2015;54(5):445–450 PMID: 25385929
Chapter 5
1. Fox E, et al. Drug therapy in neonates and pediatric patients. In: Atkinson AJ, et al, eds. Principles of
Clinical Pharmacology. 2007:359–373
2. Wagner CL, et al. J Perinatol. 2000;20(6):346–350 PMID: 11002871
3. Intravenous ceftriaxone (marketed as Rocephin and generics) and calcium drug-drug interaction:
potential risk for cardiovascular adverse events in neonates. US Food and Drug Administration.
http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm189806.htm#IntravenousCeftriax
MarketedasRocephinandGenericsandCalciumDrug-DrugInteraction:PotentialRiskforCardiovascul
AdverseEventsinNeonates. Accessed September 19, 2016
4. Martin E, et al. Eur J Pediatr. 1993;152(6):530–534 PMID: 8335024
5. Rours IG, et al. Pediatrics. 2008;121(2):e321–e326 PMID: 18245405
6. American Academy of Pediatrics. Chlamydial infections. In: Kimberlin DW, et al, eds. Red Book: 20
Report of the Committee on Infectious Diseases. 2015:284–294
7. Hammerschlag MR, et al. Pediatr Infect Dis J. 1998;17(11):1049–1050 PMID: 9849993
8. Zar HJ. Paediatr Drugs. 2005;7(2):103–110 PMID: 15871630
9. Honein MA, et al. Lancet. 1999;354(9196):2101–2105 PMID: 10609814
10. Laga M, et al. N Engl J Med. 1986;315(22):1382–1385 PMID: 3095641
11. Workowski KA, et al. MMWR Recomm Rep. 2015;64(RR-3):1–137 PMID: 26042815
12. Newman LM, et al. Clin Infect Dis. 2007;44(S3):S84–S101 PMID: 17342672
13. MacDonald N, et al. Adv Exp Med Biol. 2008;609:108–130 PMID: 18193661
14. American Academy of Pediatrics. Gonococcal infections. In: Kimberlin DW, et al, eds. Red Book: 20
Report of the Committee on Infectious Diseases. 2015:356–367
15. Cimolai N. Am J Ophthalmol. 2006;142(1):183–184 PMID: 16815280
16. Marangon FB, et al. Am J Ophthalmol. 2004;137(3):453–458 PMID: 15013867
Previous Page Next Page